

# Margret Schottelius

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3319154/publications.pdf>

Version: 2024-02-01

84  
papers

6,139  
citations

61984

43  
h-index

69250

77  
g-index

87  
all docs

87  
docs citations

87  
times ranked

5189  
citing authors

#	ARTICLE	IF	CITATIONS
1	<sup>68</sup> Ga- and <sup>177</sup> Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1169-1176.	5.0	432
2	<sup>177</sup> Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1006-1013.	5.0	432
3	Ligands for Mapping $\alpha$ - $\beta$ -Integrin Expression in Vivo. <i>Accounts of Chemical Research</i> , 2009, 42, 969-980.	15.6	285
4	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with <sup>177</sup> Lu- and <sup>90</sup> Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 248-251.	5.0	201
5	<sup>99m</sup> Tc-based Prostate-specific Membrane Antigen- $\alpha$ radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 75, 659-666.	1.9	195
6	Prostate-specific Membrane Antigen- $\alpha$ radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. <i>European Urology</i> , 2015, 68, 530-534.	1.9	192
7	PET of CXCR4 Expression by a <sup>68</sup> Ga-Labeled Highly Specific Targeted Contrast Agent. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1803-1810.	5.0	182
8	Molecular imaging targeting peptide receptors. <i>Methods</i> , 2009, 48, 161-177.	3.8	181
9	<i>In vivo</i> molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. <i>EMBO Molecular Medicine</i> , 2015, 7, 477-487.	6.9	180
10	Two-step methodology for high-yield routine radiohalogenation of peptides: ( <sup>18</sup> F)-labeled RGD and octreotide analogs. <i>Journal of Nuclear Medicine</i> , 2004, 45, 892-902.	5.0	179
11	Preclinical Evaluation and First Patient Application of <sup>99m</sup> Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 235-242.	5.0	170
12	Systemic Radioligand Therapy with <sup>177</sup> Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 382-391.	0.4	166
13	Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. <i>Theranostics</i> , 2015, 5, 618-630.	10.0	162
14	Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. <i>EJNMMI Research</i> , 2014, 4, 63.	2.5	137
15	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 855-861.	5.0	122
16	PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 302-312.	4.6	120
17	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe <sup>68</sup> Ga-Pentixafor. <i>Journal of Nuclear Medicine</i> , 2015, 56, 410-416.	5.0	108
18	First <sup>18</sup> F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography. <i>Clinical Cancer Research</i> , 2004, 10, 3593-3606.	7.0	104

#	ARTICLE	IF	CITATIONS
19	Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. <i>Protein Engineering, Design and Selection</i> , 2007, 20, 273-284.	2.1	104
20	Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. <i>Theranostics</i> , 2016, 6, 849-861.	10.0	102
21	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. <i>Theranostics</i> , 2017, 7, 1589-1597.	10.0	102
22	CXCR4-directed theranostics in oncology and inflammation. <i>Annals of Nuclear Medicine</i> , 2018, 32, 503-511.	2.2	98
23	Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer <sup>68</sup> Ga-Pentixafor for PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 499-506.	5.0	94
24	Improvement of Pharmacokinetics of Radioiodinated Tyr <sup>3</sup> -Octreotide by Conjugation with Carbohydrates. <i>Bioconjugate Chemistry</i> , 2002, 13, 1021-1030.	3.6	90
25	[ <sup>111</sup> In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. <i>EJNMMI Research</i> , 2015, 5, 68.	2.5	88
26	Value of <sup>111</sup> In- $\epsilon$ -prostate-specific membrane antigen ( $\epsilon$ -PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. <i>BJU International</i> , 2017, 120, 40-47.	2.5	88
27	Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. <i>Radiochimica Acta</i> , 2004, 92, .	1.2	85
28	[ <sup>177</sup> Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. <i>Theranostics</i> , 2017, 7, 2350-2362.	10.0	84
29	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523.	1.9	81
30	Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 71-78.	5.0	76
31	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. <i>Theranostics</i> , 2018, 8, 369-383.	10.0	68
32	Synthesis of Novel 1,4,7,10-Tetraazacyclodecane-1,4,7,10-Tetraacetic Acid (DOTA) Derivatives for Chemoselective Attachment to Unprotected Polyfunctionalized Compounds. <i>Chemistry - A European Journal</i> , 2007, 13, 6082-6090.	3.3	65
33	Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance. <i>Journal of Nuclear Medicine</i> , 2020, 61, 13-19.	5.0	62
34	<sup>18</sup> F-Fluoroglucoosylation of peptides, exemplified on cyclo(RGDfK). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1469-1474.	6.4	59
35	Gluc-Lys([ <sup>18</sup> F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [ <sup>111</sup> In]DTPA-octreotide. <i>Journal of Nuclear Medicine</i> , 2006, 47, 566-73.	5.0	54
36	Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydrate on the pharmacokinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 28-38.	6.4	51

#	ARTICLE	IF	CITATIONS
37	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 932-940.	3.5	50
38	Twins in spirit - episode I: comparative preclinical evaluation of [ <sup>68</sup> Ga]DOTATATE and [ <sup>68</sup> Ga]HA-DOTATATE. <i>EJNMMI Research</i> , 2015, 5, 22.	2.5	47
39	<sup>213</sup> Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 67-73.	1.0	47
40	Chemoselective hydrazone formation between HYNIC-functionalized peptides and 18F-fluorinated aldehydes. <i>Nuclear Medicine and Biology</i> , 2006, 33, 173-183.	0.6	46
41	A Conformationally Frozen Peptoid Boosts CXCR4 Affinity and Anti-HIV Activity. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 8110-8113.	13.8	45
42	Inpatient Comparison of <sup>111</sup> In-PSMA I&T SPECT/CT and Hybrid <sup>68</sup> Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e397-e402.	1.3	45
43	Chemokine receptor “ Directed imaging and therapy. <i>Methods</i> , 2017, 130, 63-71.	3.8	45
44	Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 131-133.	2.1	44
45	Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction. <i>Journal of Nuclear Medicine</i> , 2020, 61, 234-241.	5.0	42
46	New Developments in Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 167-171.	5.0	41
47	Development of Novel <sup>68</sup> Ga- and <sup>18</sup> F-Labeled GnRH-I Analogues with High GnRHR-Targeting Efficiency. <i>Bioconjugate Chemistry</i> , 2008, 19, 1256-1268.	3.6	40
48	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. <i>Bioconjugate Chemistry</i> , 2020, 31, 375-395.	3.6	38
49	Modulation of Pharmacokinetics of Radioiodinated Sugar-Conjugated Somatostatin Analogues by Variation of Peptide Net Charge and Carbohydration Chemistry. <i>Bioconjugate Chemistry</i> , 2005, 16, 429-437.	3.6	37
50	Pharmacophoric Modifications Lead to Superpotent <sup>123</sup> I Integritin Ligands with Suppressed <sup>21</sup> I Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3410-3417.	6.4	35
51	<i>CXCR4</i> Is a Potential Target for Diagnostic PET/CT Imaging in Barrett's Dysplasia and Esophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1048-1061.	7.0	34
52	Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007. <i>EJNMMI Research</i> , 2018, 8, 30.	2.5	33
53	A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. <i>Theranostics</i> , 2020, 10, 8264-8280.	10.0	33
54	[ <sup>99m</sup> Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. <i>EJNMMI Research</i> , 2020, 10, 45.	2.5	33

#	ARTICLE	IF	CITATIONS
55	The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. <i>EJNMMI Research</i> , 2016, 6, 36.	2.5	32
56	Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 231-244.	1.0	31
57	Rapid and high-yield solution-phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. <i>Tetrahedron Letters</i> , 2003, 44, 2393-2396.	1.4	28
58	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer. <i>Journal of Leukocyte Biology</i> , 2021, 109, 969-989.	3.3	28
59	N-Terminal Sugar Conjugation and C-Terminal Thr-for-Thr(ol) Exchange in Radioiodinated Tyr3-octreotide: A Effect on Cellular Ligand Trafficking in Vitro and Tumor Accumulation in Vivo. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2778-2789.	6.4	25
60	Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. <i>EJNMMI Research</i> , 2018, 8, 84.	2.5	23
61	In Vivo Targeting of CXCR4 New Horizons. <i>Cancers</i> , 2021, 13, 5920.	3.7	23
62	First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. <i>Tomography</i> , 2016, 2, 85-93.	1.8	22
63	Twins in spirit part II: DOTATATE and high-affinity DOTATATE the clinical experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1158-1165.	6.4	20
64	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e549-e552.	1.9	19
65	Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo a comparison to [68Ga]pentixafor. <i>EJNMMI Research</i> , 2016, 6, 70.	2.5	18
66	[123I]Mtr-TOCA, a radioiodinated and carbohydrate analogue of octreotide: scintigraphic comparison with [111In]octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 45-52.	6.4	14
67	Orthogonally Protected Artificial Amino Acid as Tripod Ligand for Automated Peptide Synthesis and Labeling with [ <sup>99m</sup> Tc(OH) <sub>2</sub> ] <sub>3</sub> (CO) <sub>3</sub> ] <sup>+</sup> . <i>Bioconjugate Chemistry</i> , 2013, 24, 26-35.	3.6	13
68	Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo. <i>EJNMMI Research</i> , 2019, 9, 75.	2.5	13
69	An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. <i>Tetrahedron Letters</i> , 2015, 56, 6602-6605.	1.4	10
70	[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 2.	3.9	10
71	Click Chemistry in the Design and Production of Hybrid Tracers. <i>ACS Omega</i> , 2019, 4, 12438-12448.	3.5	10
72	Twins in spirit: DOTATATE and high-affinity DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1789-1789.	6.4	9

#	ARTICLE	IF	CITATIONS
73	Effect of Carbohydration on the Theranostic Tracer PSMA I&T. ACS Omega, 2018, 3, 8278-8287.	3.5	9
74	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	6.4	8
75	Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 156-157.	5.0	7
76	Twins in spirit part IV â€“ [177Lu] high affinity DOTATATE. Nuklearmedizin - NuclearMedicine, 2017, 56, 1-8.	0.7	6
77	â€œLuke! Luke! Donâ€™t! Itâ€™s a trap!â€”spotlight on bias in animal experiments in nuclear oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1024-1026.	6.4	6
78	CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrettâ€™s esophagus. EJNMMI Research, 2022, 12, 2.	2.5	6
79	From Theranostics to Immunotheranostics: the Concept. Nuclear Medicine and Molecular Imaging, 2020, 54, 81-85.	1.0	3
80	Production of clinical radiopharmaceuticals: general pharmaceutical and radioanalytical aspects. Journal of Radioanalytical and Nuclear Chemistry, 2017, 311, 1551-1557.	1.5	2
81	The role of fluorescent and hybrid tracers in radioguided surgery in urogenital malignancies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 261-270.	0.7	2
82	MP82-10 PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	1
83	Perspectives on translational molecular imaging and therapy: an overview of key questions to be addressed. EJNMMI Research, 2022, 12, .	2.5	1
84	Abstract 1304: AbYlinkTM: A site-selective labeling method for preclinical imaging of therapeutic antibodies. , 2021, , .		0